Lung Cancer


Smoking and Cancer: Understand the Risk and What You Can Do to Control It (05-8-2018)

CancerConnect News: Smoking tobacco cigarettes is responsible for drastically increasing the risk of the developing lung cancer— the number-one cause of cancer-related deaths in the U.S—as well as several other types of cancer (not to mention additional... Continue Reading

Alcensa Provides Longer Symptom Improvement than Xalkori in ALK-positive Lung Cancer (04-24-2018)

CancerConnect News: Alecensa (alectinib) provides longer symptom improvement than Xalkori (crizotinib) in ALK-positive non-small-cell lung cancer (NSCLC), according to results presented at the European Lung Cancer Congress in in Geneva, Switzerland.1 About... Continue Reading

Overall Health, Not Just Age, is an Important Factor in Treatment of Non-Small Cell Lung Cancer (04-11-2018)

Younger patients with non-small cell lung cancer (NSCLC) are more likely to receive treatment than older patients, regardless of overall health and prognosis, according to the results of a study published in the Journal of Clinical Oncology. Lung cancer... Continue Reading

Managing Side Effects From EGFR Inhibitors (04-10-2018)

CancerConnect News: Epidermal Growth Factor Receptor (EGFR) inhibitor drugs are a type of precision cancer medicine commonly used to treat lung, colon, head and neck and other cancers that over express the EGFR.  There are several EGFR inhibitor drugs... Continue Reading

E-cigarettes May Help Adults Switch From Cigarettes but Encourage Smoking in Teens (02-1-2018)

By AMERICAN HEART ASSOCIATION NEWS CancerConnect News: E-cigarettes can be highly addictive, and kids who use them are more likely to start smoking regular cigarettes, concluded a panel of public health experts. A report released this week by the National... Continue Reading

Roswell Park Research Identifies Link between Smoking, Sex Hormones and Lung Cancer (01-29-2018)

CancerConnect News:  The risk of developing non-small cell lung cancer (NSCLC) is higher for women and smokers according to the results of a recent study published by a team of doctors led by Christine Ambrosone, PhD, Chair of Cancer Prevention and Control... Continue Reading

FDA Broadens Gilotrif Indication to Previously Untreated, Metastatic NSCLC with Other Non-Resistant EGFR Mutations (01-24-2018)

CancerConnect News: The Food and Drug Administration (FDA) has granted approval to Gilotrif®  (afatinib) for a broadened indication in first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant... Continue Reading

Keytruda in Combination with Alimta and Platinum Chemotherapy Improves Survival in Non Small Cell Lung Cancer (01-17-2018)

CancerConnect News: Keytruda (pembrolizumab) is the first PD1 Inhibitor to demonstrate improved overall survival when combined with chemotherapy as primary treatment for metastatic non-squamous non-small cell lung cancer (NSCLC). The KEYNOTE-189 clinical... Continue Reading

Tagrisso Improves Progression-free Survival in Asian EGFR-mutated Lung Cancer Patients (01-15-2018)

CancerConnect News: Tagrisso (osimertinib) improves progression-free survival compared to standard first line therapy in Asian patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). 1,2 Lung cancer is the number... Continue Reading

Ulixertinib A First-in-class ERK Inhibitor Shows Early Efficacy in Patients With Advanced Cancers (01-8-2018)

CancerConnect News: The novel ERK1/2 kinase inhibitor ulixertinib displayed an acceptable safety profile and had clinical activity in patients whose cancers had mutations in the MAPK cell-signaling pathway, according to data from a recent phase 1 clinical... Continue Reading

« Previous PageNext Page »